Atria Investments Inc Trims Stock Position in Glaukos Corporation $GKOS

Atria Investments Inc decreased its stake in Glaukos Corporation (NYSE:GKOS) by 33.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,550 shares of the medical instruments supplier’s stock after selling 1,296 shares during the quarter. Atria Investments Inc’s holdings in Glaukos were worth $263,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GKOS. Xponance Inc. boosted its position in Glaukos by 5.8% in the 1st quarter. Xponance Inc. now owns 3,843 shares of the medical instruments supplier’s stock worth $378,000 after purchasing an additional 210 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of Glaukos by 88.7% in the 1st quarter. Victory Capital Management Inc. now owns 140,411 shares of the medical instruments supplier’s stock valued at $13,819,000 after purchasing an additional 66,009 shares during the period. OneAscent Financial Services LLC purchased a new stake in Glaukos during the first quarter worth $408,000. Teachers Retirement System of The State of Kentucky grew its position in Glaukos by 1.4% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 28,879 shares of the medical instruments supplier’s stock valued at $2,842,000 after buying an additional 409 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new position in Glaukos in the first quarter valued at $478,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Price Performance

Glaukos stock opened at $92.76 on Thursday. The company has a fifty day simple moving average of $84.15 and a 200-day simple moving average of $91.25. The firm has a market capitalization of $5.33 billion, a price-to-earnings ratio of -60.23 and a beta of 0.81. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $163.71.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.53%. The firm had revenue of $133.54 million for the quarter, compared to analyst estimates of $122.55 million. During the same period in the previous year, the business posted ($0.28) earnings per share. Glaukos’s quarterly revenue was up 38.1% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Analyst Ratings Changes

GKOS has been the topic of several recent analyst reports. Zacks Research lowered shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 15th. William Blair upgraded Glaukos to a “strong-buy” rating in a research report on Thursday, July 31st. Stifel Nicolaus set a $115.00 price objective on Glaukos in a research report on Monday, October 27th. Wells Fargo & Company upped their target price on Glaukos from $120.00 to $122.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Finally, Needham & Company LLC lifted their price target on shares of Glaukos from $115.00 to $117.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.08.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.